Table 1.
Cpd | Percent viability | |||||
---|---|---|---|---|---|---|
0.01 μM | 0.1 μM | 1 μM | 10 μM | 100 μM | ||
MCF-7 | 1 | 95.8 ± 1.6 | 91.5 ± 3.4 | 88.6 ± 3.3 | 84.8∗ ± 1.6 | 78.8∗ ± 0.3 |
2 | 99.4 ± 1.2 | 94.8 ± 3.3 | 91.1 ± 3.2 | 90.3 ± 2.4 | 85.9∗ ± 1.6 | |
3 | 99.1 ± 0.3 | 95.1 ± 3.4 | 94.0 ± 2.5 | 92.8 ± 1.7 | 90.5∗ ± 0.3 | |
4 | 99.8 ± 0.5 | 96.0 ± 0.5 | 94.5 ± 3.1 | 91.1 ± 2.4 | 87.9∗ ± 0.6 | |
5 | 98.3 ± 1.2 | 91.8 ± 2.7 | 88.9 ± 2.8 | 86.9∗ ± 1.7 | 80.2∗ ± 1.2 | |
6 | 97.5 ± 1.5 | 93.2 ± 3.8 | 90.4 ± 3.4 | 88.2∗ ± 2.1 | 80.3∗ ± 1.7 | |
| ||||||
SAOS-2 | 1 | 98.9 ± 0.8 | 95.1 ± 0.9 | 92.1 ± 0.9 | 80.4∗ ± 0.9 | 70.1∗ ± 0.2 |
2 | 99.2 ± 0.6 | 97.4 ± 2.0 | 94.5 ± 1.3 | 92.8 ± 1.6 | 89.3∗ ± 1.5 | |
3 | 97.4 ± 1.0 | 96.8 ± 0.9 | 91.9 ± 1.7 | 84.7 ± 3.4 | 66.2∗ ± 1.2 | |
4 | 98.4 ± 0.7 | 95.8 ± 0.8 | 92.7 ± 0.4 | 90.1 ± 0.9 | 84.7∗ ± 1.0 | |
5 | 97.0 ± 1.5 | 92.9 ± 0.8 | 90.9 ± 0.5 | 85.4∗ ± 0.5 | 77.1∗ ± 0.5 | |
6 | 96.6 ± 0.8 | 93.6 ± 0.7 | 92.6 ± 1.9 | 88.5∗ ± 1.2 | 76.2∗ ± 0.9 | |
| ||||||
MG-63 | 1 | 88.2 ± 0.1 | 82.3 ± 1.2 | 74.9∗ ± 2.0 | 61.3∗ ± 0.4 | 40.4∗ ± 0.5 |
2 | 95.9 ± 2.7 | 88.8 ± 2.0 | 81.1∗ ± 0.3 | 74.9∗ ± 1.4 | 70.9∗ ± 0.6 | |
3 | 96.7 ± 2.0 | 92.2 ± 1.6 | 87.4 ± 1.2 | 80.8∗ ± 0.2 | 64.3∗ ± 1.1 | |
4 | 98.1 ± 0.4 | 93.2 ± 1.3 | 87.2∗ ± 0.8 | 79.8∗ ± 2.0 | 60.2∗ ± 1.7 | |
5 | 93.1 ± 0.9 | 83.4 ± 1.2 | 78.1∗ ± 0.8 | 67.7∗ ± 1.1 | 54.7∗ ± 2.1 | |
6 | 91.1 ± 0.7 | 86.2 ± 0.8 | 82.2 ± 1.2 | 73.0∗ ± 1.2 | 63.4∗ ± 0.4 |
Cells were treated with test compounds for 72 h and viability was determined using SRB assay. Data are expressed as mean ± SD; n = 6. ∗Significantly different from control untreated cells (p < 0.05).